Table 1.
Summary of the treatment modalities adopted for epithelial ingrowth following different ocular procedures47–66
| Study | Surgical procedure/condition | Number of cases | Treatment modality | Outcome |
| Stark47 | NA | 12 |
|
Visual acuity of 6/12 (20/40) or better |
| Naumann and Küchle48 | NA | NA | Complete excision of all epithelial layers with a full-thickness corneoscleral graft | NA |
| Nagra and Raber49 | Corneal transplant | 1 |
|
16 months corneal transplant was clear with no signs of rejection or epithelialisation across the endothelial surface, iris or intraocular lens |
| Tomlins et al50 | Cataract surgery | 1 |
|
Poor visual prognosis |
| Vinciguerra et al51 | Cataract surgery |
|
1 week Visual acuity remained 20/50 |
|
| Lindfield et al52 | LASIK | 2 | Nd:YAG laser | Complete resolution with no recurrence |
| Kucukevcilioglu and Hurmeric53 | LASIK | 1 | Nd:YAG laser | 15 months Total regression |
| Thulasi et al54 | SMILE | Multiple failed interventions such as two flap lifts, epithelial scrapings and flap edge suturing After removal of the epithelial cells from the surface, periphery and interface, the liquid sealant (ReSure; Ocular Therapeutix, Bedford, Massachusetts, USA) was applied to the flap edges using a foam-tipped applicator. Solidification of the sealant then occurred within 20 s, becoming a soft, pliable hydrogel |
Decreased corneal haze and no recurrence | |
| Ni et al55 | Cataract surgery and subsequent uneventful (DSAEK) ACIOL |
2 |
|
|
| Chen et al56 | LASIK | 12 | Mechanical debridement of the ingrowth and placement of fibrin tissue glue | No complications No loss of vision |
| Chan et al57 | SMILE | 1 |
|
Corneal haze subsided and became visually insignificant |
| Kymionis et al58 | LASIK | 1 | Combined PRK and CXL | 12 months no recurrence or progression of ectasia |
| Gupta et al59 | Chronic corneal neovascularisation | 14 | Intrastromal bevacizumab (0.05–0.1 mL of 2.5 mg/0.1 mL) 1–3 injections/eye prior to corneal grafting |
No evidence of recurrence of neovascularisation or graft rejection in the transplant group |
| Khurana et al60 | Pterygium surgery and phacoemulsification | 1 | No treatment | NA |
| Jenkins et al61 | Combined cataract and DMEK | 1 | Nd:YAG laser | Four months No recurrence |
| Hata-Mizuno et al62 | PKP Cataract surgery |
1 | PKP | ↑IOP postoperatively, and glaucoma drops were applied
|
| Kankariya et al63 | SMILE | 3 | Manual debridement after fashioning a flap using the CIRCLE software | No recurrence in all three cases |
| Dua et al64 | NA | NA | Mechanical removal with alcohol swab application | Risk for infection |
| Salari et al65 | Glaucoma surgery | 1 | One dose of weekly intracameral MTX (400 mg/0.1 mL) | No recurrence |
| de Rojas Silva et al66 | SMILE | 1 | De-epithelialisation of an area of 6 mm | One month 20/20 |
ACIOL, anterior chamber intraocular lens; BSS, balanced salt solution; CXL, corneal crosslinking; DMEK, Descemet's membrane endothelial keratoplasty; DSAEK, Descemet’s stripping automated endothelial keratoplasty; ECCE, extracapsular cataract extraction; 5-FU, 5-fluorouracil; GDD, glaucoma drainage device; Iˆ, Increased; IOP, intraocular pressure; LASIK, laser in situ keratomileusis; MTX, methotrexate; NA, not applicable/not available; Nd:YAG, neodymium-yttrium aluminium garnet; PCIOL, posterior chamber intraocular lens; PKP, penetrating keratoplasty; PRK, photorefractive keratectomy; SMILE, small incision lenticule extraction.